388 related articles for article (PubMed ID: 19791434)
1. [Edema as a measure for severity of chronic venous insufficiency and efficacy of its treatment].
Sapelkin SV
Angiol Sosud Khir; 2008; 14(3):79-81. PubMed ID: 19791434
[TBL] [Abstract][Full Text] [Related]
2. Controlled studies of Daflon 500 mg in chronic venous insufficiency.
Geroulakos G; Nicolaides AN
Angiology; 1994 Jun; 45(6 Pt 2):549-53. PubMed ID: 8203786
[TBL] [Abstract][Full Text] [Related]
3. [The drug therapy of chronic venous insufficiency (a trial of the clinical use of the preparation Detralex)].
Iablokov EG; Bogachev VIu; Domoradskaia AI
Ter Arkh; 1996; 68(10):80-1. PubMed ID: 9026954
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic potential of micronized purified flavonoid fraction (MPFF) of diosmin and hesperidin in treatment chronic venous disorder].
Hnátek L
Vnitr Lek; 2015 Sep; 61(9):807-14. PubMed ID: 26465280
[TBL] [Abstract][Full Text] [Related]
5. [Certain aspects of pathogenesis of hemorheological and trophic disturbances and their pharmacological correction in patients with chronic venous insufficiency].
Aliev SA; Ibishov KG; Aliev ES
Vestn Khir Im I I Grek; 2008; 167(2):39-43. PubMed ID: 18522184
[TBL] [Abstract][Full Text] [Related]
6. Effects of purified micronized flavonoid fraction (Detralex) on prophylactic treatment of adjuvant arthritis with methotrexate in rats.
Rovenský J; Svík K; Rovenská E; Stvrtinová V; Stancíková M
Isr Med Assoc J; 2008 May; 10(5):377-80. PubMed ID: 18605365
[TBL] [Abstract][Full Text] [Related]
7. Is There a Difference in the Clinical Efficacy of Diosmin and Micronized Purified Flavonoid Fraction for the Treatment of Chronic Venous Disorders? Review of Available Evidence.
Cazaubon M; Benigni JP; Steinbruch M; Jabbour V; Gouhier-Kodas C
Vasc Health Risk Manag; 2021; 17():591-600. PubMed ID: 34556990
[TBL] [Abstract][Full Text] [Related]
8. Advantage of a micronized flavonoidic fraction (Daflon 500 mg) in comparison with a nonmicronized diosmin.
Amato C
Angiology; 1994 Jun; 45(6 Pt 2):531-6. PubMed ID: 8203783
[TBL] [Abstract][Full Text] [Related]
9. Treatment of rat adjuvant arthritis with flavonoid (Detralex), methotrexate, and their combination.
Rovenský J; Stancíková M; Rovenská E; Stvrtina S; Stvrtinová V; Svík K
Ann N Y Acad Sci; 2009 Sep; 1173():798-804. PubMed ID: 19758231
[TBL] [Abstract][Full Text] [Related]
10. [Microcirculation end effect of detralex in patients with chronic venous insufficiency of the lower extremities].
Sirotin BZ; Zhmerenetskĭ KV
Angiol Sosud Khir; 2003; 9(3):60-5. PubMed ID: 14657934
[TBL] [Abstract][Full Text] [Related]
11. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids.
Jantet G
Angiology; 2002; 53(3):245-56. PubMed ID: 12025911
[TBL] [Abstract][Full Text] [Related]
12. Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency.
Ramelet AA
Angiology; 2001 Aug; 52 Suppl 1():S49-56. PubMed ID: 11510597
[TBL] [Abstract][Full Text] [Related]
13. Daflon 500 mg: symptoms and edema clinical update.
Ramelet AA
Angiology; 2005; 56 Suppl 1():S25-32. PubMed ID: 16193223
[TBL] [Abstract][Full Text] [Related]
14. [Risk factors of chronic venous insufficiency of the lower extremities and possibilities of its medication in therapeutic practice].
Oganov RG; Savel'ev VS; Shal'nova SA; Kirienko AI; Zolotukhin IA
Ter Arkh; 2006; 78(4):68-72. PubMed ID: 16821427
[TBL] [Abstract][Full Text] [Related]
15. Flavonoids. A review of the pharmacology and therapeutic efficacy of Daflon 500 mg in patients with chronic venous insufficiency and related disorders.
Struckmann JR; Nicolaides AN
Angiology; 1994 Jun; 45(6):419-28. PubMed ID: 8203767
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials.
Kakkos SK; Nicolaides AN
Int Angiol; 2018 Apr; 37(2):143-154. PubMed ID: 29385792
[TBL] [Abstract][Full Text] [Related]
17. A randomised controlled trial of micronised purified flavonoid fraction vs placebo in patients with chronic venous disease.
Danielsson G; Jungbeck C; Peterson K; Norgren L
Eur J Vasc Endovasc Surg; 2002 Jan; 23(1):73-6. PubMed ID: 11748952
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic aspects of a phlebotropic drug in CVI-associated edema.
Ramelet AA
Angiology; 2000 Jan; 51(1):19-23. PubMed ID: 10667639
[TBL] [Abstract][Full Text] [Related]
19. Double blind study of the pharmacodynamic and clinical activities of 5682 SE in venous insufficiency. Advantages of the new micronized form.
Cospite M; Dominici A
Int Angiol; 1989; 8(4 Suppl):61-5. PubMed ID: 2698903
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms in experimental venous valve failure and their modification by Daflon 500 mg.
Pascarella L; Lulic D; Penn AH; Alsaigh T; Lee J; Shin H; Kapur V; Bergan JJ; Schmid-Schönbein GW
Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):102-10. PubMed ID: 17890112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
